Glaukos Corp (NYSE:GKOS) CFO Joseph E. Gilliam sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $70.03, for a total value of $350,150.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of NYSE:GKOS traded down $1.31 during trading on Thursday, reaching $68.01. The stock had a trading volume of 201,402 shares, compared to its average volume of 316,346. Glaukos Corp has a 1-year low of $26.75 and a 1-year high of $70.91.
Separately, Zacks Investment Research downgraded Glaukos from a “hold” rating to a “sell” rating in a report on Tuesday, January 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Glaukos has an average rating of “Buy” and an average price target of $58.20.
TRADEMARK VIOLATION WARNING: This piece was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.chaffeybreeze.com/2019/02/21/joseph-e-gilliam-sells-5000-shares-of-glaukos-corp-gkos-stock.html.
Glaukos Company Profile
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.
Recommended Story: Hedge Funds Explained
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.